Erdafitinib Plus Cetrelimab Elicits Durable Responses in Metastatic Urothelial Carcinoma
Erdafitinib alone or in combination with cetrelimab has shown activity in a phase 2 trial of patients with FGFR-altered metastatic urothelial carcinoma.
Diagnosis & Disease Information
Neoadjuvant dd-MVAC Bests Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer
Neoadjuvant dd-MVAC improves overall and disease-specific survival vs gemcitabine-cisplatin in muscle-invasive bladder cancer, a phase 3 trial suggests.
Erdafitinib Bests Chemotherapy in FGFR-Altered Metastatic Urothelial Carcinoma
Erdafitinib improves survival vs chemotherapy in patients with metastatic urothelial carcinoma and select FGFR alterations who were previously treated with immune checkpoint inhibitors, a phase 3 trial suggests.
Update on Bladder Cancer Risk Factors
A recent review provided an update on traditional and novel risk factors for bladder cancer that may help guide prevention efforts.
Trimodality Therapy and Radical Cystectomy Produce Similar Outcomes in MIBC
Trimodality therapy produces similar oncologic outcomes as radical cystectomy in patients with muscle-invasive bladder cancer, a new study suggests.
Early Death May Be Common in Cancer Patients Taking Immune Checkpoint Inhibitors
Results of a real-world study suggest that early death may be common among cancer patients taking immune checkpoint inhibitors.
5-ARIs May Protect Against Bladder Cancer Progression
Use of 5α-reductase inhibitors prior to a bladder cancer diagnosis may reduce patients’ risks for disease progression.
High TMB Associated With Better Outcomes of ICI Therapy in Advanced Cancers
Patients with advanced cancer have better outcomes if they have high TMB prior to treatment with an ICI, new research suggests.
AUA, SUO Issue New Guideline on Nonmetastatic UTUC
The new guideline is intended to limit toxicity and improve cancer control and survival in patients with UTUC.
Associations Between Cancer and COVID-19 Death “More Substantial” in Women
The risk of in-hospital death from COVID-19 for patients with cancer differs by sex and cancer type, according to a new study.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...